Volume 39, Issue 2 pp. 115-128
NASPGHAN Clinical Guidelines

Guideline for the Evaluation of Cholestatic Jaundice in Infants: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Virginia Moyer MD, MPH

Virginia Moyer MD, MPH

Houston, Texas

Search for more papers by this author
Deborah K. Freese MD

Deborah K. Freese MD

Rochester, Minnesota

Search for more papers by this author
Peter F. Whitington MD

Peter F. Whitington MD

Chicago, Illinois

Search for more papers by this author
Alan D. Olson MD

Alan D. Olson MD

Malvern, Pennsylvania

Search for more papers by this author
Fred Brewer MD

Fred Brewer MD

Santa Rosa, California

Search for more papers by this author
Richard B. Colletti MD

Richard B. Colletti MD

Burlington, Vermont

Search for more papers by this author
Melvin B. Heyman MD, MPH

Melvin B. Heyman MD, MPH

San Francisco, California

Search for more papers by this author
First published: 01 August 2004
Citations: 46

Abstract

For the primary care provider, cholestatic jaundice in infancy, defined as jaundice caused by an elevated conjugated bilirubin, is an uncommon but potentially serious problem that indicates hepatobiliary dysfunction. Early detection of cholestatic jaundice by the primary care physician and timely, accurate diagnosis by the pediatric gastroenterologist are important for successful treatment and a favorable prognosis. The Cholestasis Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition has formulated a clinical practice guideline for the diagnostic evaluation of cholestatic jaundice in the infant. The Cholestasis Guideline Committee, consisting of a primary care pediatrician, a clinical epidemiologist (who also practices primary care pediatrics), and five pediatric gastroenterologists, based its recommendations on a comprehensive and systematic review of the medical literature integrated with expert opinion. Consensus was achieved through the Nominal Group Technique, a structured quantitative method.

The Committee examined the value of diagnostic tests commonly used for the evaluation of cholestatic jaundice and how those interventions can be applied to clinical situations in the infant. The guideline provides recommendations for management by the primary care provider, indications for consultation by a pediatric gastroenterologist, and recommendations for management by the pediatric gastroenterologist.

The Cholestasis Guideline Committee recommends that any infant noted to be jaundiced at 2 weeks of age be evaluated for cholestasis with measurement of total and direct serum bilirubin. However, breast-fed infants who can be reliably monitored and who have an otherwise normal history (no dark urine or light stools) and physical examination may be asked to return at 3 weeks of age and, if jaundice persists, have measurement of total and direct serum bilirubin at that time.

This document represents the official recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition on the evaluation of cholestatic jaundice in infants. The American Academy of Pediatrics has also endorsed these recommendations. These recommendations are a general guideline and are not intended as a substitute for clinical judgment or as a protocol for the care of all patients with this problem.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.